MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma
MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma
The bispecific antibody teclistamab produced responses in nearly two-thirds of patients with relapsed or refractory multiple myeloma who had triple-class exposure to an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->